Test Details: Colorectal cancer, nonsmall cell lung cancer (NSCLC), and pancreatic carcinomas are three of the most frequent causes of cancer mortality in the world. Established therapies are targeted on the epidermal growth factor receptor (EGFR), such as Panitumumab and Cetuximab treatment for metastatic colorectal carcinoma, Gefitinib for NSCLC, or Erlotinib for NSCLC and for pancreatic carcinoma. Treatment success using Cetuximab and Panitumumab depends on a nonmutated KRAS gene; the treatment is ineffective if the KRAS gene has any mutations particularly in codons 12 and 13. Thus, the KRAS mutational status is a predictive marker for anti-EGFR therapy.